Use of Bone-Modifying Agents in Australian Men with Castration-Resistant Prostate Cancer (CRPC)

被引：0
|
作者：
Anton, Angelyn [1 ]
Parente, Phillip [2 ,3 ]
Azad, Arun [4 ]
Weickhardt, Andrew [5 ]
Wong, Shirley [6 ]
Shapiro, Julia [3 ]
Torres, Javier [7 ]
Parnis, Francis [8 ]
Semira, Christine [1 ]
Gibbs, Peter [1 ,6 ]
Tran, Ben [1 ,9 ]
Pezaro, Carmel [2 ,3 ]
机构：
[1] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[2] Eastern Hlth, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
[4] Monash Hlth, Melbourne, Vic, Australia
[5] Olivia Newton John Canc Wellness & Res Ctr, Melbourne, Vic, Australia
[6] Western Hlth, Melbourne, Vic, Australia
[7] Goulburn Valley Hlth, Melbourne, Vic, Australia
[8] Adelaide Canc Ctr, Adelaide, SA, Australia
[9] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs100
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [41] ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC)
    Smith, Matthew Raymond
    Antonarakis, Emmanuel S.
    Ryan, Charles J.
    Berry, William R.
    Shore, Neal
    Liu, Glenn
    Alumkal, Joshi J.
    Higano, Celestia S.
    Maneval, Edna Chow
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [42] Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).
    Armstrong, Andrew J.
    Edenbrandt, Lars
    Bondesson, Eva
    Anand, Aseem
    Nordle, Orjan
    Carducci, Michael Anthony
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Dependence of Castration-Resistant Prostate Cancer (CRPC) Stem Cells on CRPC-Associated Fibroblasts
    Adisetiyo, Helty
    Liang, Mengmeng
    Liao, Chun-Peng
    Jeong, Joseph H.
    Cohen, Michael B.
    Roy-Burman, Pradip
    Frenkel, Baruch
    JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (09) : 1170 - 1176
  • [44] Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer
    Swami, Umang
    Yap, Jeffrey T.
    Agarwal, Neeraj
    JAMA ONCOLOGY, 2020, 6 (02) : 225 - 226
  • [45] Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
    Hussain, Maha
    Fizazi, Karim
    Saad, Fred
    Rathenborg, Per
    Shore, Neal
    Ferreira, Ubirajara
    Ivashchenko, Petro
    Demirhan, Eren
    Modelska, Katharina
    Phung, De
    Krivoshik, Andrew
    Sternberg, Cora N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26): : 2465 - 2474
  • [46] Novel agents for the management of castration-resistant prostate cancer
    Haddad, Housam
    Garcia, Jorge A.
    CURRENT OPINION IN UROLOGY, 2012, 22 (03) : 175 - 182
  • [47] New Agents for the Management of Castration-Resistant Prostate Cancer
    Cersosimo, Robert J.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (11) : 1518 - 1528
  • [48] Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)
    Gross, Mitchell E.
    Dorff, Tanya B.
    Quinn, David I.
    Diaz, Patricia M.
    Castellanos, Olga O.
    Agus, David B.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E11 - E21
  • [49] MLL translocation in two castration-resistant prostate cancer (CRPC) patients.
    Chowdry, Rajasree Pia
    Ledet, Elisa M.
    Phelan, Mary C.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [50] Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC).
    Mahon, K. L.
    Chatfield, M. D.
    Lee-Ng, M.
    Breit, S. N.
    Brown, D. A.
    Molloy, M. P.
    Marx, G. M.
    Pavlakis, N.
    Boyer, M. J.
    Stockler, M. R.
    Wykes, R.
    Henshall, S. M.
    Sutherland, R. L.
    Horvath, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345